Unknown Company Form SCHEDULE 13D — Oct 1, 2026
Timothy Warbington, President and CEO of Creative Medical Technology Holdings, filed a Schedule 13D disclosing beneficial ownership of 1,040,762 shares, or 13.7% of the issuer's 7,592,557 shares outstanding, alongside Creative Acquisition Corp. (CAC) holding 1,000,000 shares (13.2%). The stake stems from a September 24, 2026 Stock Purchase Agreement under which the issuer bought 4,000,000 shares of BioDefense, Inc. from CAC for $200,000 in cash plus 1,000,000 restricted shares of the issuer, giving the issuer 80% control of BioDefense and CAC the remaining 20%.
Key figures
- Shares Owned
- 1040762
- Cash paid
- $200,000
- Cac shares owned
- 1000000
- Shares outstanding
- 7592557
- Issuer shares issued
- 1000000
- Percent of class cac
- 13.2%
- Option exercise price
- 16.9
- Biodefense shares sold
- 4000000
- Percent of class warbington
- 13.7%
- Biodefense ownership post deal
- Issuer 80%, CAC 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.